STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Verastem VSTM Form 4: CEO 10b5-1 stock sales disclosed

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Verastem, Inc. (VSTM) reported insider stock sales by its President and CEO, who is also a director. The reporting person sold 2,000 shares of common stock on each of 11/21/2025, 11/24/2025, and 11/25/2025, all at a price of $10 per share. These transactions are marked with transaction code "S," indicating open market or private sales.

After these sales, the reporting person beneficially owned 432,818 shares of Verastem common stock directly. The filing notes that the sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person, which is intended to provide an affirmative defense for trading while limiting discretion over the timing and amount of trades.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Paterson Dan

(Last) (First) (Middle)
C/O VERASTEM, INC., 117 KENDRICK ST.,
SUITE 500

(Street)
NEEDHAM MA 02494

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Verastem, Inc. [ VSTM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/21/2025 S(1) 2,000(1) D $10 436,818 D
Common Stock 11/24/2025 S(1) 2,000(1) D $10 434,818 D
Common Stock 11/25/2025 S(1) 2,000(1) D $10 432,818 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
/s/ Daniel Calkins, Attorney in Fact 11/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Verastem (VSTM) report in this Form 4?

The President and CEO of Verastem, Inc. (VSTM), who is also a director, reported three sales of common stock, each involving 2,000 shares executed on 11/21/2025, 11/24/2025, and 11/25/2025.

At what price were the Verastem (VSTM) shares sold by the insider?

For each of the three reported transactions, the Verastem common shares were sold at a price of $10 per share, according to the Form 4.

How many Verastem (VSTM) shares does the insider own after these sales?

Following the reported transactions, the insider beneficially owned 432,818 shares of Verastem common stock in direct ownership.

Were the Verastem (VSTM) insider sales made under a Rule 10b5-1 plan?

Yes. The explanation states that the reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

What is the insider’s relationship to Verastem (VSTM)?

The reporting person is both a director and an officer of Verastem, serving as its President and CEO.

Is this Verastem (VSTM) Form 4 filed by one or multiple reporting persons?

The Form 4 indicates it is filed by one reporting person, not a group filing.
Verastem

NASDAQ:VSTM

VSTM Rankings

VSTM Latest News

VSTM Latest SEC Filings

VSTM Stock Data

801.40M
70.82M
0.82%
89.08%
25.94%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEEDHAM